Exploring the FDA’s Flexibility With Novel Orphan Therapies, Neurological Rare Disease Special Report, Supplement to Neurology Reviews

An interview with Frank Sasinowski was published in a Neurological Rare Disease Special Report, a Supplement to Neurology Reviews. In the interview, Mr. Sasinowski discusses how FDA has consistently exercised reasonable, appropriate, science-based flexibility in its review and approval of rare disease therapies.

If you have any questions regarding the above information, please contact:
Frank J. Sasinowski (202) 737-4287 fsasinowski@hpm.com